Cost, affordability and cost-effectiveness of strategies to control tuberculosis in countries with high HIV prevalence
Open Access
- 12 December 2005
- journal article
- research article
- Published by Springer Nature in BMC Public Health
- Vol. 5 (1)
- https://doi.org/10.1186/1471-2458-5-130
Abstract
Background The HIV epidemic has caused a dramatic increase in tuberculosis (TB) in East and southern Africa. Several strategies have the potential to reduce the burden of TB in high HIV prevalence settings, and cost and cost-effectiveness analyses can help to prioritize them when budget constraints exist. However, published cost and cost-effectiveness studies are limited. Methods Our objective was to compare the cost, affordability and cost-effectiveness of seven strategies for reducing the burden of TB in countries with high HIV prevalence. A compartmental difference equation model of TB and HIV and recent cost data were used to assess the costs (year 2003 US$ prices) and effects (TB cases averted, deaths averted, DALYs gained) of these strategies in Kenya during the period 2004–2023. Results The three lowest cost and most cost-effective strategies were improving TB cure rates, improving TB case detection rates, and improving both together. The incremental cost of combined improvements to case detection and cure was below US$15 million per year (7.5% of year 2000 government health expenditure); the mean cost per DALY gained of these three strategies ranged from US$18 to US$34. Antiretroviral therapy (ART) had the highest incremental costs, which by 2007 could be as large as total government health expenditures in year 2000. ART could also gain more DALYs than the other strategies, at a cost per DALY gained of around US$260 to US$530. Both the costs and effects of treatment for latent tuberculosis infection (TLTI) for HIV+ individuals were low; the cost per DALY gained ranged from about US$85 to US$370. Averting one HIV infection for less than US$250 would be as cost-effective as improving TB case detection and cure rates to WHO target levels. Conclusion To reduce the burden of TB in high HIV prevalence settings, the immediate goal should be to increase TB case detection rates and, to the extent possible, improve TB cure rates, preferably in combination. Realising the full potential of ART will require substantial new funding and strengthening of health system capacity so that increased funding can be used effectively.Keywords
This publication has 22 references indexed in Scilit:
- Lessons Learned from Use of Highly Active Antiretroviral Therapy in AfricaClinical Infectious Diseases, 2005
- Achieving the WHO/UNAIDS antiretroviral treatment 3 by 5 goal: what will it cost?The Lancet, 2004
- Seizing the opportunity to capitalise on the growing access to HIV treatment to expand HIV preventionThe Lancet, 2004
- Tuberculosis epidemics driven by HIV: is prevention better than cure?Published by Rockefeller University Press ,2003
- Tuberculosis epidemics driven by HIVAIDS, 2003
- Antiretroviral Drugs for Tuberculosis Control in the Era of HIV/AIDSScience, 2003
- The Growing Burden of TuberculosisArchives of internal medicine (1960), 2003
- Costs and effectiveness—the impact of economic studies on TB controlTuberculosis, 2003
- Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidenceThe Lancet, 2002
- Progression to symptomatic disease in people infected with HIV-1 in rural Uganda: prospective cohort study Commentary: Virus, host, or environment?BMJ, 2002